MDS is a stem cell disorder after all

Siddhartha Jaiswal; Benjamin L Ebert

doi:10.1016/j.ccr.2014.06.001

MDS is a stem cell disorder after all

Cancer Cell. 2014 Jun 16;25(6):713-4. doi: 10.1016/j.ccr.2014.06.001.

Authors

Siddhartha Jaiswal¹, Benjamin L Ebert²

Affiliations

¹ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
² Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 24937455
DOI: 10.1016/j.ccr.2014.06.001

Abstract

Myelodysplastic syndrome (MDS) has long been presumed to be a stem cell disorder, but rigorous formal proof has been lacking. In this issue of Cancer Cell, Woll and colleagues demonstrate that driver mutations occurring in MDS definitively occur in cells with a stem cell phenotype.

Publication types

Comment

MeSH terms

Animals
Humans
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / pathology*
Neoplastic Stem Cells / physiology*